Difelikefalin for Treating Itch in Dialysis Patients
Author Information
Author(s): Cai Xiaoyue, Wu Guiming, Lin Yan, Yang Lichuan
Primary Institution: Chengdu BOE Hospital, Chengdu, China
Hypothesis
Can difelikefalin effectively treat uremic pruritus in hemodialysis patients?
Conclusion
Difelikefalin is effective in reducing pruritus in patients with uremia, with mostly mild adverse effects.
Supporting Evidence
- Difelikefalin showed significant improvement in WI-NRS scores compared to placebo.
- The meta-analysis included 9 trials with a total of 4,118 participants.
- Adverse events were mostly mild, including diarrhea and dizziness.
- Difelikefalin is a selective kappa opioid receptor agonist that does not enter the CNS.
- Patients reported a decrease in itch severity on multiple scales.
- Risk of death was not significantly different between difelikefalin and placebo groups.
- Overall quality assessment of included studies was satisfactory.
Takeaway
Difelikefalin helps people with itchy skin who are on dialysis feel better, and it usually doesn't cause serious problems.
Methodology
A systematic review and meta-analysis of randomized controlled trials was conducted to evaluate the efficacy and safety of difelikefalin.
Potential Biases
Minimal risk of bias was noted in most studies, but some had high quality.
Limitations
Some studies included had biases in random assignment or blinding methods, and further evidence is needed for long-term efficacy and safety.
Participant Demographics
Patients aged 18 and older with end-stage kidney disease undergoing hemodialysis.
Statistical Information
P-Value
p<0.00001
Confidence Interval
95% CI 1.67–2.33
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website